ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0758

Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients

Dana Wiens1, Irene Smolik1, Xiaobo Meng1, Vidyanand Anaparti1, Hani El-Gabalawy1 and Liam O'Neil1, 1University of Manitoba, Winnipeg, MB, Canada

Meeting: ACR Convergence 2020

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), autoimmune diseases, Health Assessment Questionnaire (HAQ), Rheumatoid Factor, risk factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The preclinical stage of Rheumatoid Arthritis (RA) is characterized by seropositivity for anti-citrullinated protein antibodies (ACPA). We (PubMed ID 30861615), and others, have shown that ACPA seropositivity is prevalent in the first-degree relatives (FDR) of RA patients. While ACPA is highly predictive of RA development in individuals who were selected by healthcare providers based on having joint symptoms such as arthralgia, the association between ACPA and self-reported symptoms in an unselected population of at-risk FDR has not been well studied. Because it has been proposed that the ACPA themselves may induce joint symptoms in the absence of joint inflammation, we sought to determine whether ACPA seropositivity is associated with self-reported symptoms and functional impairment in a large, unselected, cohort of at-risk Indigenous North American (INA) FDR of RA patients.  

Methods: Baseline demographics, Health Assessment Questionnaire (HAQ), and arthritis symptom survey data were obtained from a cohort of 607 unaffected FDR of RA patients. ACPA were detected using commercial kits (CCP2 or CCP3.1) and the manufacturer’s cut-off was used to define seropositivity. Associations between ACPA status and the self-report variables were analyzed by unsupervised univariate correlation, followed by logistic regression to identify variables that were independently associated with ACPA seropositivity.   

Results: 51 (8.4%) individuals were ACPA positive at baseline. Because smoking was prevalent in the cohort (85.4%), we were not able to demonstrate a clear relationship with ACPA seropositivity.  Although joint symptoms were common amongst FDR (53.6%), they were not associated with ACPA seropositivity. Mean HAQ scores were higher in ACPA positive individuals compared to ACPA negative (0.313 vs 0.197, p = 0.14), but this did not reach statistical significance. Unexpectedly, we found that compared to FDR from urban settings, FDR from rural communities were twice as likely to be ACPA seropositive (11.5% vs. 5.2%, p < 0.001). Logistic regression modelling showed that Rural status (odds ratio (OR) 3.2, 1.5 to 7.6), Difficulty lifting a glass (OR 4.3, 1.1 to 17.2), and Difficulty walking on a flat surfaces (OR 2.9, 1.1 to 7.6) were independently associated with ACPA seropositivity, after adjusting for age and sex.   

Conclusion: Although we were unable to demonstrate a relationship between joint symptoms and ACPA seropositivity, functional disability is associated with ACPA, even in the absence of detectable joint inflammation. The discordance in ACPA seropositivity between rural and urban locations is intriguing and warrants further investigation. 


Disclosure: D. Wiens, None; I. Smolik, None; X. Meng, None; V. Anaparti, None; H. El-Gabalawy, None; L. O'Neil, None.

To cite this abstract in AMA style:

Wiens D, Smolik I, Meng X, Anaparti V, El-Gabalawy H, O'Neil L. Anti-citrullinated Protein Antibodies Are Associated with Functional Disability in Unaffected First-degree Relatives of Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-citrullinated-protein-antibodies-are-associated-with-functional-disability-in-unaffected-first-degree-relatives-of-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-citrullinated-protein-antibodies-are-associated-with-functional-disability-in-unaffected-first-degree-relatives-of-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology